IDEAYA Biosciences Inc. (IDYA)
NASDAQ: IDYA
· Real-Time Price · USD
21.98
-0.41 (-1.83%)
At close: Jun 17, 2025, 3:59 PM
21.92
-0.27%
After-hours: Jun 17, 2025, 04:43 PM EDT
-1.83% (1D)
| Bid | 21 |
| Market Cap | 1.93B |
| Revenue (ttm) | 7M |
| Net Income (ttm) | -306.31M |
| EPS (ttm) | -3.65 |
| PE Ratio (ttm) | -6.02 |
| Forward PE | -7.49 |
| Analyst | Buy |
| Ask | 23.45 |
| Volume | 690,347 |
| Avg. Volume (20D) | 1,428,734 |
| Open | 22.16 |
| Previous Close | 22.39 |
| Day's Range | 21.68 - 22.30 |
| 52-Week Range | 13.45 - 44.42 |
| Beta | 0.02 |
About IDYA
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol IDYA
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for IDYA stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts7 months ago
+0.34%
IDEAYA Biosciences shares are trading higher after...
Unlock content with
Pro Subscription
11 months ago
-3.37%
IDEAYA Biosciences shares are trading lower after the company priced a $263 million public offering of 228,572 common shares and pre-funded warrants at $35 per share.
1 month ago · seekingalpha.com
Ideaya Biosciences: Value Beyond Darovasertib With ADC Program IDE849Ideaya Biosciences, Inc. is advancing darovasertib in a phase 2/3 trial for HLA-A2-negative metastatic uveal melanoma patients, with mPFS data expected by end of 2025. Ideaya plans a phase 3 study of ...
2 months ago · seekingalpha.com
Ideaya Biosciences: These Prices Are Probably Going To Look Cheap Sooner Than LaterIDEAYA Biosciences' valuation has declined over 50% since mid-2024, prompting a re-evaluation of its investment potential. The most advanced program, darovasertib, targets tumors with GNAQ/GNA11 mutat...
